The US Food and Drug Administration has approved bemotrizinol, ending a quarter-century gap in new sunscreen active ingredient approvals. The last FDA-authorized sunscreen ingredient entered the market in 1999, leaving American consumers with limited formulation options compared to their European and Asian counterparts. Bemotrizinol, which has demonstrated a robust safety profile through decades of widespread use abroad, now expands the spectrum of broad-spectrum UV protection available domestically. This approval signals a potential shift in how US regulators integrate internationally vetted dermatological actives, potentially accelerating future ingredient approvals. The expanded ingredient roster may enable manufacturers to develop more effective and diverse sunscreen formulations tailored to different skin types and preferences. For dermatologists and consumers alike, bemotrizinol’s authorization represents meaningful progress in accessible sun protection technology. Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: FDA Approves Bemotrizinol: First New Sunscreen Ingredient in 25 Years →
